Cargando…

Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion

Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately,...

Descripción completa

Detalles Bibliográficos
Autores principales: Klafack, Sandro, Schröder, Lars, Jin, Yeonhwa, Lenk, Matthias, Lee, Pei-Yu, Fuchs, Walter, Avarre, Jean-Christophe, Bergmann, Sven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448810/
https://www.ncbi.nlm.nih.gov/pubmed/36068296
http://dx.doi.org/10.1038/s41541-022-00525-6
_version_ 1784784148964048896
author Klafack, Sandro
Schröder, Lars
Jin, Yeonhwa
Lenk, Matthias
Lee, Pei-Yu
Fuchs, Walter
Avarre, Jean-Christophe
Bergmann, Sven M.
author_facet Klafack, Sandro
Schröder, Lars
Jin, Yeonhwa
Lenk, Matthias
Lee, Pei-Yu
Fuchs, Walter
Avarre, Jean-Christophe
Bergmann, Sven M.
author_sort Klafack, Sandro
collection PubMed
description Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately, there is only one commercial vaccine available which is not approved in most countries. Therefore, there is an urgent need for new, safe and available vaccines. In this study, a live attenuated vaccine virus was generated by cell culture passages of virulent KHV, and shown to protect carp or koi after immersion or oral application against wild type challenge. An advantage of boost immunization was demonstrated, especially after oral application. Vaccination induced no or mild clinical signs and protecting antibodies have been measured. Additionally, the vaccine virus allowed differentiation of infected from vaccinated animals (DIVA) by PCR. The attenuation of the newly generated vaccine was tracked down to a partial deletion of open reading frame 150. This was confirmed by the generation of engineered ORF150 deletion mutants of wild-type KHV which exhibited a similar attenuation in vivo.
format Online
Article
Text
id pubmed-9448810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94488102022-09-08 Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion Klafack, Sandro Schröder, Lars Jin, Yeonhwa Lenk, Matthias Lee, Pei-Yu Fuchs, Walter Avarre, Jean-Christophe Bergmann, Sven M. NPJ Vaccines Article Since the end of the1990ies, Cyprinid herpesvirus 3 (also known as koi herpesvirus, KHV) has caused mass mortality events of koi and common carp all over the globe. This induced a high economic impact, since the KHV disease cannot be cured up to now, but only prevented by vaccination. Unfortunately, there is only one commercial vaccine available which is not approved in most countries. Therefore, there is an urgent need for new, safe and available vaccines. In this study, a live attenuated vaccine virus was generated by cell culture passages of virulent KHV, and shown to protect carp or koi after immersion or oral application against wild type challenge. An advantage of boost immunization was demonstrated, especially after oral application. Vaccination induced no or mild clinical signs and protecting antibodies have been measured. Additionally, the vaccine virus allowed differentiation of infected from vaccinated animals (DIVA) by PCR. The attenuation of the newly generated vaccine was tracked down to a partial deletion of open reading frame 150. This was confirmed by the generation of engineered ORF150 deletion mutants of wild-type KHV which exhibited a similar attenuation in vivo. Nature Publishing Group UK 2022-09-06 /pmc/articles/PMC9448810/ /pubmed/36068296 http://dx.doi.org/10.1038/s41541-022-00525-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Klafack, Sandro
Schröder, Lars
Jin, Yeonhwa
Lenk, Matthias
Lee, Pei-Yu
Fuchs, Walter
Avarre, Jean-Christophe
Bergmann, Sven M.
Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title_full Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title_fullStr Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title_full_unstemmed Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title_short Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion
title_sort development of an attenuated vaccine against koi herpesvirus disease (khvd) suitable for oral administration and immersion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448810/
https://www.ncbi.nlm.nih.gov/pubmed/36068296
http://dx.doi.org/10.1038/s41541-022-00525-6
work_keys_str_mv AT klafacksandro developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT schroderlars developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT jinyeonhwa developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT lenkmatthias developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT leepeiyu developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT fuchswalter developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT avarrejeanchristophe developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion
AT bergmannsvenm developmentofanattenuatedvaccineagainstkoiherpesvirusdiseasekhvdsuitablefororaladministrationandimmersion